RT Journal Article
SR Electronic
T1 A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.13.21256973
DO 10.1101/2021.05.13.21256973
A1 Sivapalasingam, Sumathi
A1 Lederer, David J.
A1 Bhore, Rafia
A1 Hajizadeh, Negin
A1 Criner, Gerard
A1 Hosain, Romana
A1 Mahmood, Adnan
A1 Giannelou, Angeliki
A1 Somersan-Karakaya, Selin
A1 O’Brien, Meagan
A1 Boyapati, Anita
A1 Parrino, Janie
A1 Musser, Bret
A1 Labriola-Tompkins, Emily
A1 Ramesh, Divya
A1 Purcell, Lisa A.
A1 Gulabani, Daya
A1 Kampman, Wendy
A1 Waldron, Alpana
A1 Gong, Michelle Ng
A1 Saggar, Suraj
A1 Sperber, Steven J.
A1 Menon, Vidya
A1 Stein, David K.
A1 Sobieszczyk, Magdalena E.
A1 Park, William
A1 Aberg, Judith A.
A1 Brown, Samuel M.
A1 Kosmicki, Jack A.
A1 Horowitz, Julie E.
A1 Ferreira, Manuel A.
A1 Baras, Aris
A1 Kowal, Bari
A1 DiCioccio, A. Thomas
A1 Akinlade, Bolanle
A1 Nivens, Michael C.
A1 Braunstein, Ned
A1 Herman, Gary
A1 Yancopoulos, George D.
A1 Weinreich, David M.
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/05/28/2021.05.13.21256973.abstract
AB BACKGROUND Sarilumab (anti-interleukin-6 receptor-α monoclonal antibody) may attenuate the inflammatory response in Covid-19.METHODS We performed an adaptive, phase 2/3, randomized, double-blind, placebo-controlled trial of intravenous sarilumab 200 mg or 400 mg in adults hospitalized with Covid-19. The phase 3 primary analysis population (cohort 1) was patients with critical Covid-19 receiving mechanical ventilation (MV) randomized to sarilumab 400 mg or placebo. The primary end point for phase 3 was the proportion of patients with ≥1-point improvement in clinical status from baseline to day 22.RESULTS Four-hundred fifty-seven (457) and 1365 patients were randomized and treated in phases 2 and 3, respectively. Among phase 3 critical patients receiving MV (n=289; 34.3% on corticosteroids), the proportion with ≥1-point improvement in clinical status (alive not receiving MV) at day 22 was 43.2% in sarilumab 400 mg and 35.5% in placebo (risk difference [RD] +7.5%; 95% confidence interval [CI], –7.4 to 21.3; P=0.3261), representing a relative risk improvement of 21.7%. Day 29 all-cause mortality was 36.4% in sarilumab 400 mg versus 41.9% in placebo (RD –5.5%; 95% CI, –20.2 to 8.7; relative risk reduction 13.3%). In post hoc analyses pooling phase 2 and 3 critical patients receiving MV, the hazard ratio (HR) for death in sarilumab 400 mg compared with placebo was 0.76 (95% CI, 0.51 to 1.13) overall, improving to 0.49 (95% CI, 0.25 to 0.94) in patients receiving corticosteroids at baseline.CONCLUSION In hospitalized patients with Covid-19 receiving MV, numerical benefits with sarilumab did not achieve statistical significance, but benefit may be greater in patients receiving corticosteroids. A larger study is required to confirm this observed numerical benefit.(ClinicalTrials.gov number, NCT04315298)Competing Interest StatementICMJE disclosure forms provided by the authors are available with the full text of this article.Clinical TrialNCT04315298Funding StatementSupported by Regeneron Pharmaceuticals, Inc. and Sanofi. Certain aspects of this project have been funded in whole or in part with federal funds from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under OT number: HHSO100201700020C.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was developed by the sponsor (Regeneron Pharmaceuticals Inc.). Data were collected by the study investigators and analyzed by the sponsor. Ethics approval was obtained from the following ethics review boards: WCG IRB, Puyallup, WA (IRB00000533); Oregon Health & Science University, Portland, OR (MOD00027616); Institutional Review Board University of Florida, Gainesville, FL (IRB202000779); Columbia University, Human Research Protection Office and IRBs, New York, NY (IRB-AAAS9615); Johns Hopkins Medicine, Office of Human Subjects Research, IRB, Baltimore, MD (IRB00246576/CIR00058074); NYU School Of Medicine, New York, NY (I20-00351_MOD03); Northwestern University IRB, Chicago, IL (STU00212239-MOD0012); Westchester Medical Center, NY Medical College, Office of Research Administration, Valhalla, NY (IRBReg#00000428); Portland Health and Services IRB Providence, St. Johns, Portland, OR (MOD2020001024); Cornell Weill Medicine IRB, New York, NY (IRB00009419); Providence St. Joseph IRB, Renton, WA (MOD2020001029); Providence Health and Services IRB, Portland, OR (MOD2020000519); Ascension St. John Hospital, Tulsa, OK (IRB#00001980); Geisinger IRB, Danville, PA (IRB#0008345). All patients provided written informed consent before participating in the trial. The trial was overseen by an IDMC.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesQualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification. Submit requests to https://vivli.org/.